Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
40.89
+1.82 (4.66%)
Dec 20, 2024, 4:00 PM EST - Market closed
Veracyte Employees
Veracyte had 815 employees as of December 31, 2023. The number of employees increased by 28 or 3.56% compared to the previous year.
Employees
815
Change (1Y)
28
Growth (1Y)
3.56%
Revenue / Employee
$521,879
Profits / Employee
-$11,372
Market Cap
3.17B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BrightSpring Health Services | 35,000 |
Envista Holdings | 12,800 |
Warby Parker | 3,473 |
NovoCure | 1,453 |
Inari Medical | 1,300 |
Amicus Therapeutics | 517 |
Denali Therapeutics | 445 |
Xenon Pharmaceuticals | 259 |
VCYT News
- 16 days ago - Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines - Business Wire
- 6 weeks ago - Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Veracyte Announces Third Quarter 2024 Financial Results - Business Wire
- 7 weeks ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 - Business Wire
- 3 months ago - New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer - Business Wire
- 3 months ago - Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors - Business Wire
- 4 months ago - Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - Business Wire